GlobeNewswire PharmaOriginal article
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
Data ReadoutpositiveVabysmoPositive
AI Analysis
Summary
Roche announced positive two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo (faricimab) demonstrating significant improvements in vision and retinal health in patients with polypoidal choroidal vasculopathy, a severe sub-type of nAMD.
Clinical Trial Data
Phase
Phase IIIb/IV
Primary Endpoint
Met
Outcome Details
Two-year data from Phase IIIb/IV SALWEEN study showed significant improvements in vision and retinal health in patients with PCV
Importance:6/10
Sentiment:
0.70
ophthalmologynAMDVabysmoclinical datatwo-year results
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 28, 2026 7:00 AM